# Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

> **NCT00201877** · PHASE2 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 25 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Velcade
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00201877
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2009-06
- **Final completion:** 2012-03
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00201877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00201877, "Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00201877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*